Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 28;42(23):2790–2799. doi: 10.1200/JCO.23.01462

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — TTD in PROs with (A) STRIDE versus sorafenib and (B) durvalumab versus sorafenib. EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; HCC, hepatocellular carcinoma; HR, hazard ratio; NR, not reached; PRO, patient-reported outcome; QLQ-C30, 30-item Quality of Life Questionnaire; QLQ-HCC18, 18-item HCC Health-Related Quality of Life Questionnaire; QoL, quality of life; STRIDE, Single Tremelimumab Regular Interval Durvalumab; TTD, time to deterioration.